The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Can Extended-release Injectable Medications Help Curb United States and Canada's Opioid Overdose Epidemic?
Open accessAbstract
Settings throughout the United States and Canada continue to face escalating overdose epidemics. Notably, history of overdose is associated with increased risk of fatal overdose. Unfortunately, despite frequent contact with health services and the well-known mortality benefits of medications for opioid use disorder (MOUD), only a fraction of overdose survivors is successfully linked to addiction care after leaving the emergency department. This may be partially explained by well-documented challenges of oral MOUD, including the need for frequent visits to the pharmacy to receive their medications, which may limit the flexibility to acquire or sustain employment, and therefore contribute to high rates of opioid addiction care discontinuation. This commentary discusses the potential fit of different extended-release injectable MOUD to circumvent limitations of oral formulations, and thereby improve linkage and retention in care of high-risk populations, such as opioid-overdose survivors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Extended-release buprenorphine may be particularly useful for populations at high risk for overdose fatalities, including survivors of opioid overdose.
“extended-release buprenorphine may be particularly useful for populations at high risk for overdose fatalities, including survivors of opioid overdose.40”
From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Flagged first, then by citations
Research works printed but not linked: 10
- Otterstatter, 2018, Patterns of health care utilization among people who overdosed from illegal drugs: a descriptive analysis using the BC Provincial Overdose Cohort, Health Promot Chronic Dis Prev Can, 38, 328, 10.24095/hpcdp.38.9.04 · DOI
- Sordo, 2017, Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies, BMJ, 357, j1550, 10.1136/bmj.j1550 · DOI · Paper page
- Caudarella, 2016, Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs, Drug Alcohol Depend, 162, 51, 10.1016/j.drugalcdep.2016.02.024 · DOI
- Sharma, 2017, Update on barriers to pharmacotherapy for opioid use disorders, Curr Psychiatry Rep, 19, 35, 10.1007/s11920-017-0783-9 · DOI
- Richardson, 2012, Addiction treatment-related employment barriers: the impact of methadone maintenance, J Subst Abuse Treat, 43, 276, 10.1016/j.jsat.2011.12.008 · DOI
- Morgan, 2019, Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort, Drug Alcohol Depend, 200, 34, 10.1016/j.drugalcdep.2019.02.031 · DOI · Paper page
- Lofwall, 2018, Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial, JAMA Intern Med, 178, 764, 10.1001/jamainternmed.2018.1052 · DOI
- Haight, 2019, Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 393, 778, 10.1016/S0140-6736(18)32259-1 · DOI · Paper page
- Neale, 2019, Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations, Harm Reduct J, 16, 25, 10.1186/s12954-019-0296-4 · DOI
- Saunders, 2020, Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders, J Subst Abuse Treat, 111, 54, 10.1016/j.jsat.2020.01.009 · DOI
Cited by
Sorted by citations
Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108764 · Cited by 67
Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29583 · Cited by 21
Metadata
- Authors
- Socías, M. E., & Nolan, S.
- Affiliations
- University of British Columbia (CA)
- ORCID
- Nolan, Seonaid
- Venue
- Journal of Addiction Medicine
- Published
- 2020-06-18
- Volume
- 15
- Issue
- 1
- Pages
- 15-17
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- PMC
- PMC8824682
- OpenAlex
- W3037562523
- Cited by
- 2
- References
- 1
- Citations by year
- 2023: 1 · 2021: 1
- FWCI
- 0.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R25DA037756)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- medication-assisted treatment, opioid overdose epidemic, retention in care, pharmacy visits, barriers to employment
- MeSH terms
- Opiate Overdose, Canada, Humans, Opioid-Related Disorders, United States, Epidemics, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
